Expert Interview
Examining the Potential Label Expansion of Rezdiffra (resmetirom) into Advanced Compensated MASH cirrhosis (F4)
Ticker(s): MDGLInstitution: MUSC
Professor and Chairman of the Department of Medicine and Hepatology
Treats approximately 50 MASH patients per year, including about 25 with F4 (compensated cirrhosis)
Primary research focus is on establishing evidence-based management strategies for common GI conditions and advancing guideline-directed care through clinical research
How do you view compensated MASH cirrhosis (F4c) as a treatment population compared with earlier-stage fibrosis, is this where pharmacologic intervention could most meaningfully alter outcomes, or is it already “too late” biologically?
Added By: sara_adminWhat safety signals would concern you most when using a thyroid hormone receptor–β agonist in F4 patients, particularly regarding cardiac risk, bone health, or hepatic decompensation?
Added By: sara_adminWhat magnitude of benefit in cirrhosis (fibrosis regression, liver stiffness reduction, or prevention of clinical events) would be required for you to routinely treat compensated F4 MASH patients with resmetirom?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
